Determinants of recurrence after successful treatment of Mycobacterium avium complex lung disease

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 10, 2015, Pages 1239-1245

  Min, J ^a   Park, J ^a   Lee, Y J ^a   Kim, S J ^a   Park, J S ^a   Cho, Y J ^a   Yoon, H I ^a   Lee, C T ^a   Lee, J H ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

Long term; MAC; Non tuberculous mycobacteria; Treatment outcome

Indexed keywords

CLARITHROMYCIN; ETHAMBUTOL; RIFAMPICIN; ANTIINFECTIVE AGENT;

ADULT; AGE; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BODY MASS; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SOUTH KOREA; SPUTUM ANALYSIS; THORAX SCINTISCANNING; TREATMENT DURATION; AGED; COMBINATION DRUG THERAPY; COMPUTER ASSISTED TOMOGRAPHY; ISOLATION AND PURIFICATION; LUNG DISEASES; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; SPUTUM; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RECURRENCE; RETROSPECTIVE STUDIES; SPUTUM; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84942755778     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0139     Document Type: Article

References (24)

1. O'Brien R J, Geiter L J, Snider D E, Jr. The epidemiology of non-tuberculous mycobacterial diseases in the United States. Results from a national survey. Am Rev Respir Dis 1987; 135: 1007-1014.
2. Park Y S, Lee C H, Lee S M, et al. Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea. Int J Tuberc Lung Dis 2010; 14: 1069-1071.
3. Martinez S, McAdams H P, Batchu C S. The many faces of pulmonary non-tuberculous mycobacterial infection. AJR Am J Roentgenol 2007; 189: 177-186.
4. Dautzenberg B, Piperno D, Diot P, et al. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest 1995; 107: 1035-1040.
5. Wallace R J, Jr, Brown B A, Griffith D E, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994; 149: 1335-1341.
6. Griffith D E, Aksamit T, Brown-Elliott B A, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
7. Roussel G, Igual J. Clarithromycin with minocycline and clofazimine for Mycobacterium avium-intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. Groupe d'Etude et de Traitement des Infections à Mycobactéries. Int J Tuberc Lung Dis 1998; 2: 462-470.
8. Field S K, Cowie R L. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003; 124: 1482-1486.
9. Wallace R J, Jr, Brown B A, Griffith D E, et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996; 153: 1766-1772.
10. Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999; 160: 866-872.
11. Hayashi M, Takayanagi N, Kanauchi T, et al. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012; 185: 575-583.
12. Field S K, Fisher D, Cowie R L. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 2004; 126: 566-581.
13. rd, Parker B C. Recent experience in the epidemiology of disease caused by atypical mycobacteria. Rev Infect Dis 1981; 3: 990-996.
14. von Reyn C F, Maslow J N, Barber T W, et al. Persistent colonisation of potable water as a source of Mycobacterium avium infection in AIDS. Lancet 1994; 343: 1137-1141.
15. Wallace R J, Jr, Zhang Y, Brown B A, et al. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med 1998; 158: 1235-1244.
16. Kim S J, Park J, Lee H, et al. Risk factors for deterioration of nodular bronchiectatic Mycobacterium avium complex lung disease. Int J Tuberc Lung Dis 2014; 18: 730-736.
17. Fujikane T, Fujiuchi S, Yamazaki Y, et al. Efficacy and outcomes of clarithromycin treatment for pulmonary MAC disease. Int J Tuberc Lung Dis 2005; 9: 1281-1287.
18. Wallace R J, Jr, Brown-Elliott B A, McNulty S, et al. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest 2014; 146: 276-282.
19. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. Int J Tuberc Lung Dis 2002; 6: 628-634.
20. Chae D R, Kim Y I, Kee S J, et al. The impact of the 2007 ATS/IDSA diagnostic criteria for non-tuberculous mycobacterial disease on the diagnosis of non-tuberculous mycobacterial lung disease. Respiration 2011; 82: 124-129.
21. Prince D S, Peterson D D, Steiner R M, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321: 863-868.
22. rd. Non-tuberculous mycobacteria from household plumbing of patients with non-tuberculous mycobacteria disease. Emerg Infect Dis 2011; 17: 419-424.
23. Wallace R J Jr, Zhang Y, Brown-Elliott B A, et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis 2002; 186: 266-273.
24. Griffith D E, Brown-Elliott B A, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 174: 928-934.